26th July 2012 - News release

SINGLE DRUG FOR PARKINSON'S, ALZHEIMER'S AND MULTIPLE SCLEROSIS

A new class of drug is being developed at Northwestern University as a single therapy for Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and traumatic brain injury by reducing inflammation in the brain. Northwestern University has been issued patents to cover this new drug class and has licensed the commercial development to a biotech company that has recently completed the first human Phase 1 clinical trial for the drug. The drugs in this class, represented by MW151 and MW189, target a particular type of brain inflammation, which they claim is a common denominator in these neurological disorders, as well as in traumatic brain injury and stroke. They claim that brain inflammation plays a major role in the progressive damage characteristic of these chronic diseases and brain injuries. For more information, go to the News release.